In the future, we will continue to refine related research, elucidate the structure-activity relationships between XTS and key IL-23/IL-17 proteins using surface plasmon resonance (SPR) and molecular docking techniques, conduct long-term toxicity tests and reproductive toxicity screening in accordance with GLP standards, and conduct comprehensive studies on anti-RA effects in other RA animal models or organoid models, with the aim of providing more comprehensive and scientific evidence for the clinical application of XTS. Here, IL17A is linked to rheumatoid arthritis.